Appili Therapeutics Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Appili Therapeutics Inc. (OTC: APLIF) is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases and biodefense indications. The company advances a pipeline of small-molecule antimicrobials and vaccines targeting unmet medical needs in areas such as acute bacterial skin and skin structure infections, pandemic influenza, and post-exposure prophylaxis against anthrax; its lead product candidate, APP13007, is a topical ozenoxacin formulation in Phase 3 trials for impetigo treatment, while other assets include APP13010 for infectious keratitis and various biodefense programs licensed from government partners. Appili operates primarily in the healthcare and biotechnology sectors, serving government agencies, healthcare providers, and patients globally with a focus on North America and international markets. Founded in 2018 and headquartered in Charlottetown, Prince Edward Island, Canada, the company collaborates with entities like the U.S. Biomedical Advanced Research and Development Authority (BARDA) on strategic initiatives. In recent developments within the last two years, Appili completed a strategic merger with Incuron in 2023 to bolster its infectious disease portfolio, secured non-dilutive funding from BARDA for its gastrointestinal acute radiation syndrome program in 2024, and reported positive Phase 2b data for its norovirus vaccine candidate in mid-2025, alongside ongoing enrollment in the APP13007 Phase 3 IMPETIGO program.
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders